Drug Trial Radar · NCT04208698
A Scintigraphy Study in Adults With Diabetic Gastroparesis
Last checked: Nov 19, 2026Latest source record: Aug 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Feb 17, 2020
Primary completion
Mar 31, 2020
Study completion Mar 31, 2020
Sponsor
- Lead sponsor
- CinDome Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
Conditions
- Diabetic Gastroparesis
Interventions
CIN-102 Dose 1Drug
Deuterated domperidone (deudomperidone)
CIN-102 Dose 2Drug
Deuterated domperidone (deudomperidone)
Placebo for CIN-102Drug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.Time frame: Baseline to Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
El Paso, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.